摘要
目的:系统论述非典型抗精神病药治疗精神分裂症临床研究和应用的进展,评价其临床疗效和安全性。方法:通过互联网查阅Medline、Pubmed、Ovid、Science Direct、Proquest及国内外相关专业杂志所公开发表的研究报道进行综合评价和分析。结果与结论:非典型抗精神病药近10年来的临床应用研究进展迅速,除氯氮平外,大多数新型非典型抗精神病药如利培酮、奥氮平、喹硫平、齐拉西酮及阿立哌唑等已成为精神分裂症各种症状维度、不同病期和复发预防的一线临床选择,特别是在不良反应方面克服了经典抗精神病药和氯氮平的诸多严重缺点,同时,各种临床研究结果已被多项应用循证医学方法的系统研究所证实。
OBJECTIVE:To systematically review the aspects of clinical usage and research progress of atypical antipsychotics in the treatment of schizophrenia( SP) and evaluate their clinical efficacy and safety. METHODS: To search medical literatures in resent years at Medline, Pubmed, Ovid, Science Direct and Proque st by internet and some reports published on medical literatures at home and ab road for an analysis. RESULTS & CONCLUSION: Clinical use and research of atypica l antipsychotics in the treatment of schizophrenia have been well-performed and the advancements have been swift. Most of new type of atypical antipsychotics, such as risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole, have already become the first line choice for the treatment of schizophrenia in diff erent level, different stage and prevention of recurrence, except for clozapine. In particular, they have obviously minimized side effects caused by classic ant ipsychotics and clozapine. Various clinical research results have been confirmed by many clinically systematic researches taking the method of evidence-based p sychiatry.
出处
《中国医院用药评价与分析》
2005年第2期75-80,共6页
Evaluation and Analysis of Drug-use in Hospitals of China
